Skip to main content
PMC home page
Journal of Medical Ethics logoLink to Journal of Medical Ethics
. 1999 Apr;25(2):200–203. doi: 10.1136/jme.25.2.200

Genetic screening with the DNA chip: a new Pandora's box?

W Henn 1
PMCID: PMC479207  PMID: 10226928

Abstract

The ethically controversial option of genetic population screening used to be restricted to a small number of rather rare diseases by methodological limitations which are now about to be overcome. With the new technology of DNA microarrays ("DNA chip"), emerging from the synthesis of microelectronics and molecular biology, methods are now at hand for the development of mass screening programmes for a wide spectrum of genetic traits. Thus, the DNA chip may be the key technology for a refined preventive medicine as well as a new dimension of eugenics. The forthcoming introduction of the DNA chip technology into medical practice urgently requires an internationally consistent framework of ethical standards and legal limitations if we do not want it to become a new Pandora's box.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin C. M., Adam S., Wiggins S., Theilmann J. L., Copley T. T., Bloch M., Squitieri F., McKellin W., Cox S., Brown S. A. Proceed with care: direct predictive testing for Huntington disease. Am J Hum Genet. 1994 Oct;55(4):606–617. [PMC free article] [PubMed] [Google Scholar]
  2. Birmingham K. Insurers admit genetic discrimination. Nat Med. 1997 Jul;3(7):710–710. doi: 10.1038/nm0797-710a. [DOI] [PubMed] [Google Scholar]
  3. Burnett L., Proos A. L., Chesher D., Howell V. M., Longo L., Tedeschi V., Yang V. A., Siafakas N., Turner G. The Tay-Sachs disease prevention program in Australia: Sydney pilot study. Med J Aust. 1995 Sep 18;163(6):298–300. doi: 10.5694/j.1326-5377.1995.tb124595.x. [DOI] [PubMed] [Google Scholar]
  4. Chee M., Yang R., Hubbell E., Berno A., Huang X. C., Stern D., Winkler J., Lockhart D. J., Morris M. S., Fodor S. P. Accessing genetic information with high-density DNA arrays. Science. 1996 Oct 25;274(5287):610–614. doi: 10.1126/science.274.5287.610. [DOI] [PubMed] [Google Scholar]
  5. Cronin M. T., Fucini R. V., Kim S. M., Masino R. S., Wespi R. M., Miyada C. G. Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays. Hum Mutat. 1996;7(3):244–255. doi: 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  6. Doherty R. A., Palomaki G. E., Kloza E. M., Erickson J. L., Haddow J. E. Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn. 1996 May;16(5):397–404. doi: 10.1002/(SICI)1097-0223(199605)16:5<397::AID-PD864>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  7. Gibbs W. W. New chip off the old block. Can DNA microprobes do for genetics what microprocessors did for computing? Sci Am. 1996 Sep;275(3):42–44. [PubMed] [Google Scholar]
  8. Hacia J. G., Brody L. C., Chee M. S., Fodor S. P., Collins F. S. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet. 1996 Dec;14(4):441–447. doi: 10.1038/ng1296-441. [DOI] [PubMed] [Google Scholar]
  9. Henn W. Predictive diagnosis and genetic screening: manipulation of fate? Perspect Biol Med. 1998 Winter;41(2):282–289. doi: 10.1353/pbm.1998.0044. [DOI] [PubMed] [Google Scholar]
  10. Hoedemaekers R., ten Have H., Chadwick R. Genetic screening: a comparative analysis of three recent reports. J Med Ethics. 1997 Jun;23(3):135–141. doi: 10.1136/jme.23.3.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hudson K. L., Rothenberg K. H., Andrews L. B., Kahn M. J., Collins F. S. Genetic discrimination and health insurance: an urgent need for reform. Science. 1995 Oct 20;270(5235):391–393. doi: 10.1126/science.270.5235.391. [DOI] [PubMed] [Google Scholar]
  12. Kaback M., Lim-Steele J., Dabholkar D., Brown D., Levy N., Zeiger K. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 1993 Nov 17;270(19):2307–2315. [PubMed] [Google Scholar]
  13. Kagamimori S., Naruse Y., Matsubara I., Li Fu B., Sokejima S., Yamagami T. Genetic and environmental effects on urinary kallikrein, catecholamines, sodium, potassium, urea nitrogen and inorganic sulfate sulfur levels in school-age twins. Hum Hered. 1996 Jan-Feb;46(1):1–6. doi: 10.1159/000154317. [DOI] [PubMed] [Google Scholar]
  14. Kozal M. J., Shah N., Shen N., Yang R., Fucini R., Merigan T. C., Richman D. D., Morris D., Hubbell E., Chee M. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996 Jul;2(7):753–759. doi: 10.1038/nm0796-753. [DOI] [PubMed] [Google Scholar]
  15. Moskowitz D. W. Genetic screening and diagnosis of disease. Mol Med Today. 1996 Jul;2(7):275–275. doi: 10.1016/1357-4310(96)30049-x. [DOI] [PubMed] [Google Scholar]
  16. Rothenberg K., Fuller B., Rothstein M., Duster T., Ellis Kahn M. J., Cunningham R., Fine B., Hudson K., King M. C., Murphy P. Genetic information and the workplace: legislative approaches and policy changes. Science. 1997 Mar 21;275(5307):1755–1757. doi: 10.1126/science.275.5307.1755. [DOI] [PubMed] [Google Scholar]
  17. Welkenhuysen M., Evers-Kiebooms G., Decruyenaere M., Van den Berghe H., Bande-Knops J., Van Gerven V. Adolescents' attitude towards carrier testing for cystic fibrosis and its relative stability over time. Eur J Hum Genet. 1996;4(1):52–62. doi: 10.1159/000472170. [DOI] [PubMed] [Google Scholar]
  18. van der Riet A. A., van Hout B. A., Rutten F. F. Cost effectiveness of DNA diagnosis for four monogenic diseases. J Med Genet. 1997 Sep;34(9):741–745. doi: 10.1136/jmg.34.9.741. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Ethics are provided here courtesy of BMJ Publishing Group

RESOURCES